Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lazar Velicki

Showing results (81-90 of 93) with videos related to

Pageof 10
Sort By:
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|May 21, 2019
Correction to: Real-World Data of Prasugrel vs. Ticagrelor in Acute Myocardial Infarction: Results from the RENAMI RegistryOvidio De Fillippo, Martina Cortese, Fabrizio D Ascenzo, et al.
Revista Espanola De Cardiologia (English Ed.)|June 30, 2018
Annual Incidence of Confirmed Stent Thrombosis and Clinical Predictors in Patients With ACS Treated With Ticagrelor or PrasugrelSergio Raposeiras-Roubín, Emad Abu-Assi, Fabrizio D'Ascenzo, et al.
European Journal of Preventive Cardiology|March 14, 2019
Long versus short dual antiplatelet therapy in acute coronary syndrome patients treated with prasugrel or ticagrelor and coronary revascularization: Insights from the RENAMI registryFabrizio D'Ascenzo, Maurizio Bertaina, Francesco Fioravanti, et al.
ESC Heart Failure|November 26, 2025
Economic burden of heart failure in Europe: A systematic review of costs and cost-effectivenessJosep Darbà, Meritxell Ascanio, Antonio Rodríguez, et al.
Cardiovascular Drugs and Therapy|July 5, 2021
Ticagrelor or Clopidogrel After an Acute Coronary Syndrome in the Elderly: A Propensity Score Matching Analysis from 16,653 Patients Treated with PCI Included in Two Large Multinational RegistriesMatteo Bianco, Alessandro Careggio, Carlo Alberto Biolè, et al.
Revista Espanola De Cardiologia (English Ed.)|July 22, 2018
Usefulness of the PARIS Score to Evaluate the Ischemic-hemorrhagic Net Benefit With Ticagrelor and Prasugrel After an Acute Coronary SyndromeSergio Raposeiras-Roubín, Berenice Caneiro Queija, Fabrizio D'Ascenzo, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|April 29, 2019
Real-World Data of Prasugrel vs. Ticagrelor in Acute Myocardial Infarction: Results from the RENAMI RegistryOvidio De Filippo, Martina Cortese, Fabrizio D Ascenzo, et al.
Thrombosis Research|June 2, 2018
Anemia in patients with acute coronary syndromes treated with prasugrel or ticagrelor: Insights from the RENAMI registryCarme Guerrero, Alberto Garay, Albert Ariza-Solé, et al.
IJID Regions|February 11, 2025
Mortality Associated with Surgical Site Infections Following Cardiac Surgery: Insights from the International ID-IRI StudyHakan Erdem, Handan Ankarali, Jaffar A Al-Tawfiq, et al.
International Journal of Cardiology|December 2, 2019
Comparative external validation of the PRECISE-DAPT and PARIS risk scores in 4424 acute coronary syndrome patients treated with prasugrel or ticagrelorMatteo Bianco, Fabrizio D'ascenzo, Sergio Raposeiras Roubin, et al.
Pageof 10

Showing results (81-90 of 93) with videos related to

Sort By:
Pageof 10
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|May 21, 2019
Correction to: Real-World Data of Prasugrel vs. Ticagrelor in Acute Myocardial Infarction: Results from the RENAMI RegistryOvidio De Fillippo, Martina Cortese, Fabrizio D Ascenzo, et al.
Revista Espanola De Cardiologia (English Ed.)|June 30, 2018
Annual Incidence of Confirmed Stent Thrombosis and Clinical Predictors in Patients With ACS Treated With Ticagrelor or PrasugrelSergio Raposeiras-Roubín, Emad Abu-Assi, Fabrizio D'Ascenzo, et al.
European Journal of Preventive Cardiology|March 14, 2019
Long versus short dual antiplatelet therapy in acute coronary syndrome patients treated with prasugrel or ticagrelor and coronary revascularization: Insights from the RENAMI registryFabrizio D'Ascenzo, Maurizio Bertaina, Francesco Fioravanti, et al.
ESC Heart Failure|November 26, 2025
Economic burden of heart failure in Europe: A systematic review of costs and cost-effectivenessJosep Darbà, Meritxell Ascanio, Antonio Rodríguez, et al.
Cardiovascular Drugs and Therapy|July 5, 2021
Ticagrelor or Clopidogrel After an Acute Coronary Syndrome in the Elderly: A Propensity Score Matching Analysis from 16,653 Patients Treated with PCI Included in Two Large Multinational RegistriesMatteo Bianco, Alessandro Careggio, Carlo Alberto Biolè, et al.
Revista Espanola De Cardiologia (English Ed.)|July 22, 2018
Usefulness of the PARIS Score to Evaluate the Ischemic-hemorrhagic Net Benefit With Ticagrelor and Prasugrel After an Acute Coronary SyndromeSergio Raposeiras-Roubín, Berenice Caneiro Queija, Fabrizio D'Ascenzo, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|April 29, 2019
Real-World Data of Prasugrel vs. Ticagrelor in Acute Myocardial Infarction: Results from the RENAMI RegistryOvidio De Filippo, Martina Cortese, Fabrizio D Ascenzo, et al.
Thrombosis Research|June 2, 2018
Anemia in patients with acute coronary syndromes treated with prasugrel or ticagrelor: Insights from the RENAMI registryCarme Guerrero, Alberto Garay, Albert Ariza-Solé, et al.
IJID Regions|February 11, 2025
Mortality Associated with Surgical Site Infections Following Cardiac Surgery: Insights from the International ID-IRI StudyHakan Erdem, Handan Ankarali, Jaffar A Al-Tawfiq, et al.
International Journal of Cardiology|December 2, 2019
Comparative external validation of the PRECISE-DAPT and PARIS risk scores in 4424 acute coronary syndrome patients treated with prasugrel or ticagrelorMatteo Bianco, Fabrizio D'ascenzo, Sergio Raposeiras Roubin, et al.
Pageof 10